The GLP-1 Podcast Show

In this episode of The GLP-1 Podcast Show, I speak with Dr. Sandra Christensen, obesity medicine specialist and founder of Integrative Medical Weight Management. We examine how GLP-1 therapies impact body composition beyond total weight loss. Dr. Christensen explores fat-free mass reduction, muscle and bone considerations, and clinical risks. She also addresses nutrition strategies, resistance training, and the importance of structured monitoring and personalized care. Listen now on all major platforms!"When evaluating weight reduction outcomes, it is essential to distinguish between fat mass and fat-free mass, because each component has different physiological roles and clinical implications."Meet the guest: Dr. Sandra Christensen is an obesity medicine specialist and founder of Integrative Medical Weight Management in Seattle. She holds advanced certification in obesity medicine and serves as a trustee for the Obesity Medicine Association and president of the Washington Obesity Society. Her work focuses on clinical strategies, patient care, and education in obesity treatment. Learn more from Dr. Sandra Christensen on The GLP-1 Podcast Show, available on all major platforms.What you will learn:(00:00) Highlight(01:07) Introduction(02:34) Body composition(04:09) Fat-free mass(07:46) Protein strategies(12:08) Resistance training(14:51) Monitoring tools(25:47) Final Questions𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.Website: The GLP-1 Podcast ShowInstagram: The GLP-1 Podcast ShowLinkedIn: The GLP-1 Podcast Show

In this episode of The GLP-1 Podcast Show, I speak with Dr. Catherine Toomer, founder of Total Weight Care Institute and a family medicine physician specializing in metabolic disease. The discussion examines long-term clinical experience using GLP-1 therapies, including dosing strategies, metabolic regulation, and patient-centered obesity care. She also explores insulin resistance, brain signaling, and emerging therapeutic applications. Listen now on all major platforms! “Appetite regulation is strongly influenced by brain signaling pathways, and correcting metabolic signaling often changes hunger perception and eating behavior without relying on willpower alone.” Meet the guest: Dr. Catherine Toomer https://www.linkedin.com/in/drtoomer/ is a family medicine physician and founder of Total Weight Care Institute, with more than fifteen years of clinical experience using GLP-1 therapies to address metabolic disease and obesity. Her work focuses on correcting metabolic dysregulation through evidence-based medical strategies and personalized care. What you will learn: (00:00) Highlight (00:31) Introduction (01:52) Metabolic disease drivers (05:33) Personalized dosing strategy (07:17) Managing side effects (19:44) Brain appetite signaling (22:40) Future applications (24:50) Final Questions 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: https://www.wisenetix.com/glp1 Instagram: https://www.instagram.com/theglp1podcast/ LinkedIn: https://www.linkedin.com/showcase/the-glp-1-podcast-show/

In this episode of The GLP-1 Podcast Show, I speak with Melissa Mitri, Registered Dietitian and weight loss expert at Melissa Mitri Nutrition, about real-world nutrition strategies for patients using GLP-1 therapies. She focuses on nutrient density, meal structure, side effect management, muscle preservation, and long-term habit building. Melissa shares clinical insights from nearly two decades of practice working directly with patients. Melissa highlights how nutrition and lifestyle optimize outcomes alongside GLP-1 medications. Listen now on all major platforms! “GLP-1 therapies shift nutrition counseling away from calorie obsession toward nutrient density, because patients eat smaller portions and every bite must support metabolic health.” Meet the guest: Melissa Mitri, MS, RD, is a Registered Dietitian, weight loss expert, and founder of Melissa Mitri Nutrition. She specializes in sustainable weight management, including nutrition support for patients using GLP-1 therapies. With nearly 20 years of clinical experience, her work focuses on nutrient density, habit formation, and evidence based care. Connect with our guest on Social Media: LinkedIn: https - www.linkedin.com/in/melissa-mitri-ms-rd-9539789/ Instagram - https://www.instagram.com/theweightloss.dietitian?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw== GLP-1 Cheat Sheet for Clinicians - https://buy.stripe.com/8wMfZa6lRaMK9jieUU What you will learn: (00:00) Highlight (00:45) Introduction (02:27) Nutrition approach (04:59) Meal timing (07:23) Side effects (12:14) Muscle preservation (17:35) Long-term habits (29:49) Final Questions 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: https://www.wisenetix.com/glp1 Instagram: https://www.instagram.com/theglp1podcast/ LinkedIn: https://www.linkedin.com/showcase/the-glp-1-podcast-show/

In this episode of The GLP-1 Podcast Show, I speak with Dr. Jens Juul Holst, Professor of Medical Physiology at the University of Copenhagen and Senior Group Leader at the Novo Nordisk Foundation Center for Basic Metabolic Research. We explore the discovery of GLP-1, its evolution into today’s leading therapies for diabetes and obesity, and the molecular and clinical mechanisms that drive their success. Listen now on all major platforms. “The incretin hormones GLP-1 and GIP amplify insulin secretion after meals, ensuring glucose tolerance and maintaining energy balance across multiple tissues.” Meet the guest: Dr. Jens Juul Holst is Professor of Medical Physiology at the University of Copenhagen and Senior Group Leader at the Novo Nordisk Foundation Center for Basic Metabolic Research. His research focuses on metabolic hormones, appetite regulation, and the pathophysiology of obesity and type 2 diabetes. Known for co-discovering GLP-1, his work has shaped modern metabolic therapy. What you will learn: (00:00) Highlight (00:35) Introduction (01:44) GLP-1 mechanism (04:37) Discovery process (07:12) Therapeutic development (10:56) Cardiovascular effects (14:45) Broader metabolic impact (20:04) Final Questions 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: https://www.wisenetix.com/glp1 Instagram: https://www.instagram.com/theglp1podcast/ LinkedIn: https://www.linkedin.com/showcase/the-glp-1-podcast-show/

The GLP-1 Podcast Show is a new podcast created to spotlight the science, perspectives, and leaders shaping the future of obesity treatment and metabolic medicine. In this first episode, we welcome Dr. Michael Schwartz, Robert H. Williams Endowed Chair and Professor of Medicine at the University of Washington, who speaks with Areesha Moiz about how GLP-1 receptor agonists reshape obesity treatment. The discussion covers adaptive responses to weight loss, brain regulation of appetite, mechanisms of long-acting drugs, and the challenges of sustaining results after treatment withdrawal. It also highlights emerging therapeutic strategies to prolong weight loss. Listen now on all major platforms!"GLP-1 receptor agonists are unique because they continuously and maximally activate their target, creating effects that natural peptides could never achieve."Meet the guest: Dr. Michael Schwartz received his MD from Rush Medical College and trained in endocrinology and metabolism at the University of Washington. He is internationally recognized for his research on brain mechanisms controlling body weight, glucose homeostasis, obesity, and diabetes. A recipient of numerous awards, Dr. Schwartz has published nearly 300 papers and directed major research institutes in Seattle. What you will learn:(00:00) Highlight(01:15) Introduction(03:26) GLP-1 drug design(07:51) Appetite regulation(10:23) Adaptive response(14:39) Weight regain(17:55) Maintenance strategies(24:44) Final Questions𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.Website: The GLP-1 Podcast ShowInstagram: The GLP-1 Podcast ShowLinkedIn: The GLP-1 Podcast Show